Ikena Oncology Investor Relations Material
Latest events
Q1 2025
8 May, 2025
Q4 2024
5 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ikena Oncology
Access all reports
Ikena Oncology is a U.S.-based biopharmaceutical company focused on developing innovative therapies targeting cancer and other immune-related diseases. The company's research centers on molecular mechanisms that drive tumor growth and immune evasion, with a focus on precision oncology and immuno-oncology approaches. Ikena’s pipeline includes treatments aimed at targeting key signaling pathways involved in cancer progression, with therapies designed to offer new options for patients with difficult-to-treat cancers. The company is headquartered in Boston, Massachusetts, and its shares are listed on NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IKNA
Country
🇺🇸 United States